Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-02-28

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Involuntary oscillations of the eyes (nystagmus) impairs vision so that affected patients, who have neurological disorders such as Multiple Sclerosis (MS) , cannot read or watch TV. Two medicines have been reported to suppress nystagmus and improve vision in such patients: gabapentin and memantine. The investigators set out to test which of these two drug was more effective by carrying out a double-blind cross-over study. In this way, we could determine which drug worked best in each patient.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Pendular Nystagmus in OPT

NCT02466191

Pendular Nystagmus Oculopalatal Tremor

COMPLETED PHASE4

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

NCT00661440

Nystagmus, Congenital Idiopathic Nystagmus, Acquired

COMPLETED PHASE2

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

NCT00799942

Nystagmus, Congenital Nystagmus, Acquired Multiple Sclerosis

TERMINATED PHASE2

Correction of Head Turn in Idiopathic Infantile Nystagmus

NCT05947331

Infantile Nystagmus Syndrome

ACTIVE_NOT_RECRUITING NA

Brain Changes in Blepharospasm

NCT00487383

Dystonia Focal Dystonia Cerebellar Disease

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study entails careful measurements of visual acuity and precise measurements of eye movements, using a contact lens device (magnetic search coil method). In this way, it is possible to make objective and reliable measurements of the effect of each drug, which are unbiased by the investigator or the patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nystagmus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gabapentin

Increasing dose to 300 mg four times per day (total of 1200 mg/day)

Group Type ACTIVE_COMPARATOR

gabapentin

Intervention Type DRUG

increasing to 1200 mg/day

Memantine

Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).

Group Type ACTIVE_COMPARATOR

memantine

Intervention Type DRUG

increasing to 40 mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

gabapentin

increasing to 1200 mg/day

Intervention Type DRUG

memantine

increasing to 40 mg/day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Neurontin Nameda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (18 years or older) males or females with acquired nystagmus that is degrading their vision

Exclusion Criteria

* Pregnant women
* Individuals who cannot describe their visual symptoms, cooperate with testing, or give informed consent
* Individuals with intolerance of gabapentin or memantine

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No